Search

Displaying results 1671 - 1680 of 8010 in total
  1. Drug

    Trovafloxacin

    go.drugbank.com/drugs/DB00685
    ApprovedWithdrawn

    Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. … It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Propylhexedrine

    go.drugbank.com/drugs/DB06714
    Approved

    It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.

  3. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  4. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.

  5. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    It also acts as a chemosterilant for male houseflies and other insects.

  6. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … Prademagene zamikeracel is a sheet-based gene therapy comprising autologous cells isolated from skin punch biopsies of patients with mutations in the collagen type VII alpha 1 chain (COL7A1) gene.

  7. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction. … Food and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

  9. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse. … Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label].

    Categories: Drugs for Treatment of Bone Diseases
  10. Drug

    Vidarabine

    go.drugbank.com/drugs/DB00194
    ApprovedWithdrawn

    A nucleoside antibiotic isolated from Streptomyces antibioticus. … It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use